TY -的T1神经丝患者髓磷脂抗体轻链含量少突细胞糖蛋白(MOG-Ab) (1783) JF -神经学乔-神经学六世- 94 - 15补充SP - 1783 AU -萨拉Mariotto AU -塞尔吉奥·法拉利盟Daniela阿尔贝蒂AU - Serena Zanzon首页i盟凯瑟琳Schanda AU -萨尔瓦多摩纳哥盟Markus Reindl AU -阿尔贝托Gajofatto Y1 - 2020/04/14 UR - //www.ez-admanager.com/content/94/15_Supplement/1783.abstract N2 -目的:评估神经丝轻链(NfL)浓度MOG-Ab-positive患者根据临床/ paraclinical特点和评价个体内的会随着时间而改变。背景:NfL的标记轴突损伤,增加患者的血清/ CSF几个神经障碍相关的临床和放射学活动。因此,NfL可能是一个有用的生物标志物监测MOG-Ab-related炎症的疾病活动条件,当然是高度异构的和不可预测的。设计/方法:可用(n = 17)血清和脑脊液样本63连续MOG-Ab-positive病人神经病理学实验室测试,维罗纳大学在2015年3月- 2019年8月使用的是活的细胞试验分析了NfL使用SIMOA Nf-light工具包(Quanterix-SR-X分析器)。六十随访28名患者的样本进行分析。临床和放射学数据采样和最后随访收集在每种情况下。结果:我们发现血清NfL值和年龄之间的显著相关抽样,老年受试者中发现水平较高(r = 0.41, p = 0.001)。此外,边界之间的相关性是指出配对血清/ CSF NfL值(r = 0.42, p = 0.09)和血清MOG-Ab效价与血清NfL水平(r = 0.15, p = 0.11)。CSF只有MOG-Ab阳性病例脑脊液NfL较高水平与血清反应阳性的相比的。Interestingly, NfL values correlated with disability at sampling (rs=0.43, p < 0.001). When analyzing follow-up samples, NfL levels decreased (n=30) or remain stable (n=23) in comparison with first measurement in most cases, including those on relapse, in parallel with a decrease of clinical disability in comparison with first event EDSS. Finally, although radiologically and clinically active patients tend to have higher NfL values in comparison with inactive ones, the difference between the groups was not significant.Conclusions: Serum NfL levels could be a potential biomarker of neurological disability in MOG-Ab positive patients to be assessed in prospective studies.Disclosure: Dr. Mariotto has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck for attending a neurological meeting.Dr. Ferrari has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Shire and Sanofi Genzyme.Dr. Alberti has nothing to disclose. Dr. Zanzoni has nothing to disclose. Dr. Schanda has nothing to disclose. Dr. Monaco has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Honoraria from Biogen. Dr. Reindl has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Chugai.. Dr. Reindl has received research support from The Neurological Research Laboratory (Markus Reindl, Medical University of Innsbruck and Tirol Kliniken), Euroimmu. Dr. Gajofatto has received research support from Merck. ER -